The variants IVS6-1G>A and IVS15+1G>A lead to aberrant splicing of the transcripts

Sara Gutiérrez-Enríquez, Verónica Coderch, Miriam Masas, Judith Balmaña, Orland Diez

► To cite this version:

Sara Gutiérrez-Enríquez, Verónica Coderch, Miriam Masas, Judith Balmaña, Orland Diez. The variants IVS6-1G>A and IVS15+1G>A lead to aberrant splicing of the transcripts. *Breast Cancer Research and Treatment*, 2008, 117 (2), pp.461-465. 10.1007/s10549-008-0154-7. hal-00486595

HAL Id: hal-00486595

<https://hal.science/hal-00486595>

Submitted on 26 May 2010

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

The variants *BRCA1* IVS6-1G>A and *BRCA2* IVS15+1G>A lead to aberrant splicing of the transcripts

Sara Gutiérrez-Enríquez · Verónica Coderch ·
Miriam Masas · Judith Balmaña · Orland Diez

Received: 31 July 2008 / Accepted: 31 July 2008 / Published online: 19 August 2008
© Springer Science+Business Media, LLC. 2008

Abstract The majority of *BRCA1* and *BRCA2* deleterious mutations and variants of unknown significance have been identified in genomic DNA and their effects at the mRNA level have not been reported. Our aim was to ascertain the pathological effect of the *BRCA1* IVS6-1G>A (c. 302-1G>A) and the *BRCA2* IVS15+1G>A (c. 7617+1G>A) variants detected in Spanish breast/ovarian cancer families. Sequencing of cDNA from the *BRCA1* IVS6-1G>A allele revealed an inappropriate splicing of exon 7. The analysis of

the *BRCA2* IVS15+1G>A allele showed the skipping of exon 15. Both alterations predicted the appearance of premature stop codons. Our findings highlight the importance of studying mutations at DNA and RNA levels in order to clarify the effect of the suspected mutation and to provide adequate counseling for breast/ovarian cancer families.

Keywords Hereditary breast cancer · *BRCA1* · *BRCA2* · Splicing mutation

An RNA analysis published online recently, showed that the *BRCA2* IVS15+2T>G caused skipping of exon 15 in RNA isolated from skin fibroblasts [Vreeswijk MPG, Kraan JN, van der Klift HM et al (2008) Intronic variants in *BRCA1* and *BRCA2* that affect RNA splicing can be reliably selected by splice-site prediction programs. Hum Mutat Published Online. doi:10.1002/humu.20811].

S. Gutiérrez-Enríquez · M. Masas · O. Diez
Fundació Institut de Recerca de l'Hospital Universitari Vall d'Hebron, Barcelona, Spain

S. Gutiérrez-Enríquez (✉)
Laboratori de Biologia Molecular, Laboratoris Clinics, Soterrani de l'Hospital Materno Infantil Vall d'Hebron, Passeig de la Vall d'Hebron 119-129, 08035 Barcelona, Spain
e-mail: sagutier@vhebron.net

V. Coderch
Facultat de Biociències, Universitat Autònoma de Barcelona, Barcelona, Spain

J. Balmaña
Unitat d'Alt Risc i Prevenció del Càncer,
Hospital Universitari Vall d'Hebron, Barcelona, Spain

O. Diez
Programa de Medicina Molecular i Genètica,
Hospital Universitari Vall d'Hebron, Barcelona, Spain

Introduction

A family history of breast cancer (BC) is one of the main risk factors for developing the disease. It is currently estimated that about 5–10% of BC are due to an inherited predisposition. Although, the number of predisposing genes is unknown, epidemiological studies provide evidence of at least two high penetrance susceptibility genes: *BRCA1* (17q21) (MIM# 113705) [1] and *BRCA2* (13q12–13) (MIM# 600185) [2].

Extensive analyses of the *BRCA1* and *BRCA2* genes have resulted in the identification of a large number of different disease-causing germ-line mutations (listed online at the Breast Cancer Information Core) [3]. Most reported disease-associated alleles of *BRCA1* and *BRCA2* have been attributed to frame-shift, nonsense or splice site alterations that lead to truncation of *BRCA1* or *BRCA2* proteins.

A large number of missense mutations, translationally silent mutations, and intron variants (especially those affecting splice sites positions) routinely encountered in clinical and research laboratories cannot be readily distinguished as either disease-associated mutations or benign polymorphisms, and they are classified as variants of uncertain significance (BIC database). This fact poses a

real challenge for risk assessment and genetic counseling of patients from cancer-prone families.

Mutations that affect intron consensus sequences at the splice and branch sites, and those that create ectopic splice sites account for 15% of point mutations associated with human genetic diseases [4]. A number of studies have demonstrated the effect of some of these splice site variants in the *BRCA1* and *BRCA2* genes at mRNA level [5–14].

Nevertheless, the majority of *BRCA1* and *BRCA2* variants have been identified in genomic DNA and their effects at the mRNA level have not been reported. Our aim was to ascertain the pathological effect of two *BRCA1* and *BRCA2* variants detected in the genetic analysis of two Spanish breast/ovarian cancer families.

Patients and methods

As part of genetic studies carried out on breast/ovarian Spanish families in the Hospital Vall d'Hebron (Barcelona), germ-line *BRCA1* and *BRCA2* mutations were screened in a proband of each family. Individuals underwent genetic counselling and signed an informed consent prior to testing.

DNA was extracted from whole blood using the Puregene Genomic DNA purification kit (Gentra System, Minneapolis, MN, USA). DNA was amplified by PCR using primers specific for the coding sequence and exon-intron boundaries. Analysis of the entire coding and flanking sequences was carried out by sequencing using BigDye Terminator V3.1 Cycle Sequencing Kit on a 3130 Genetic Analyzer (Applied Biosystems, Foster City, CA, USA). Both forward and reverse strands were sequenced.

Two sequence variants were analyzed in our study: the *BRCA1* IVS6-1G>A (c. 302-1G>A according HGVS), and the *BRCA2* IVS15+1G>A (c. 7617+1G>A according HGVS). These variants were named according to the GenBank entries NM_007294 (*BRCA1*) and NM_000059 (*BRCA2*). Their pathological significance was unknown although their location suggested that they could be deleterious.

Patients

The *BRCA1* IVS6-1G>A mutation was present in the proband and in her healthy brother. The proband was diagnosed as having bilateral BC at 40 and 52 years of age, and her mother died of BC at 61 years. No other neoplasias were reported in her family.

The *BRCA2* IVS15+1G>A mutation was detected in the proband, who was diagnosed with BC at 48 years, and in one sister, who also presented with OC and BC both diagnosed at 61 years.

Reverse transcription and amplification of the *BRCA1*/*BRCA2* coding regions

Patient peripheral blood samples were collected in EDTA tubes. Fresh peripheral blood was treated with erythrocytes lysis solution (RBC lysis solution, Qiagen Sciences, Maryland, USA). Total RNA was extracted from peripheral-blood leukocytes of carrier patients and controls using TRIzol reagent (Invitrogen, Paisley, United Kingdom) according to the manufacturer's protocol. Isolated RNA was further processed on columns from RNeasy Kit and RNase-Free DNase set to cleanup RNA and remove any DNA traces, according to the protocols provided by the manufacturer (Qiagen Sciences, Maryland, USA). The integrity of RNA purified was checked in an 1.5% agarose gel stained with ethidium bromide.

After quantification with a NanoDrop spectrophotometer (NanoDrop Technologies, Inc. Wilmington, DE, USA), one microgram of total RNA was reverse transcribed using Transcriptor High Fidelity cDNA Synthesis Kit with anchored-oligo (dT)₁₈ (Roche Diagnostics GmbH, Mannheim, Germany) according to the manufacturers' protocols.

Primers (5'–3') used to amplify the *BRCA1* coding region from exon 3 through exon 8 were: TCAAGGAACCTGTCT CCACA (forward), and GGTGTATCCGCTGCTTTGT (reverse). Primers used for exon 14 through exon 16 *BRCA2* coding region were: ACAGGCAGACCAACCAAGT (forward) and TCCACCATCAGCCAAGTGT (reverse).

For IVS6-1G>A PCR was performed to amplify the cDNA sample from one carrier and three normal controls. For the study of IVS15+1G>A a number of samples were analyzed in parallel: two positive samples and one without the mutation (all of them belonging to the same family), and one normal sample as control.

Results

After cDNA amplification of each variant the PCR products were visualized by agarose gel electrophoresis.

For *BRCA1* fragment (exons 3–8) a product of the expected size (approximately 427 bp) was obtained from all samples. Sequencing of cDNA from the carrier of the *BRCA1* IVS6-1G>A allele revealed that this allele causes inappropriate splicing of exon 7 (Fig. 1), resulting in a 10-base frameshift deletion at the beginning of exon 7 (c. 302_311del10). This alteration in the cDNA creates 14 new residues (101[^]114) and a predicted stop codon at residue 115 (p.Tyr101SerfsX15). The 10 bp differences between the two alleles made difficult to distinguish two different wild-type and mutant bands in agarose gels.

For the *BRCA2* cDNA amplified sequence (exons 14–16), the expected 561 bp DNA fragment was obtained

Fig. 1 Partial sequence of the RT-PCR products of the wild type and mutated alleles from a *BRCA1* IVS6-1G>A (c. 302-1G>A) carrier, and schema of the region of exon 6–exon 7 junction of *BRCA1* gene. Sequencing analysis revealed a 10-base frameshift deletion at the beginning of exon 7 (c. 302_311del10) and a predicted premature stop codon

from all samples and an extra shorter 379 bp fragment with less intensity was identified in the two positive patients but not in controls (data not shown). The sequence analysis indicated that the *BRCA2* IVS15+1G>A allele results in the complete skipping of exon 15, with the inclusion of seven new amino acids (2479–2485) in the BRCA2 protein and the appearance of a stop codon in position 2486 (p.Asp2479AlafsX8) (Fig. 2).

Discussion

Hundreds of different mutations and variants have been detected in *BRCA1* and *BRCA2* genes. A large number of the missense and intron variants identified so far cannot be unequivocally distinguished as either disease-associated mutations or benign polymorphisms because they have only been studied at genomic DNA level. They are

Fig. 2 Partial sequence of the RT-PCR products of the wild type and mutated alleles from a *BRCA2* IVS15+1G>A (c. 7617+1G>) carrier, and schema of the region of exon 14–exon 15–exon 16 junction of *BRCA2* gene. This alteration causes skipping of exon 15, and the appearance of a premature stop codon

classified as variants of uncertain significance (BIC database). We evaluated at the mRNA level the molecular nature and pathological effect of one *BRCA1* and *BRCA2* variants of uncertain significance, located within consensus splicing sequences. We demonstrated by cDNA sequencing the existence of aberrant splicing in both *BRCA1* IVS6-1G>A and *BRCA2* IVS15+1G>A mutations.

The *BRCA1* c. 302-1G>A (HGVS) variant has been reported once to the BIC database (IVS6-1G>A). In the same nucleotide another variant (IVS6-1G>T) was reported twice. Our analysis of IVS6-1G>A cDNA products demonstrates that this intronic substitution activates another cryptic acceptor splice site, which results in a 10 bp frameshift deletion at the beginning of exon 7. This frameshift deletion results in the addition of 14 new residues and a premature stop codon.

Other different variants located in the last intronic bases in the same splicing consensus sequence have also been reported to the BIC database: IVS6-2delA (11 times), IVS6-2A>C (one time), IVS6-2A>T (one time) and IVS6-3C>G (three times). The splice site variant IVS6-2delA has been described previously and extensively tested [15, 16]. The IVS6-2delA change clearly appeared to affect the production of mRNA from the variant allele in carrier individuals [15]. Although sequencing of the cDNA product failed to detect any deficiency in the splicing of exon 6 to exon 7, it was not possible to demonstrate if the transcript represented one or two *BRCA1* alleles, and the lack of expression in the MCF-7 cells carrying the construct containing the IVS6-2delA mutation demonstrated the disruption of the normal splicing of *BRCA1* [15]. The authors also found that the mutation directly affected mRNA stability. Furthermore, by combining these data with an assessment of the histopathological features of the breast carcinomas in carriers and mutation penetrance estimates, the authors concluded that this *BRCA1* variant conveyed an increased risk of breast cancer [15]. More recently, Chen et al. conducted a RT-PCR of the IVS6-2delA mutation and the sequencing analysis revealed the same result that we obtained studying the IVS+1G>A variant: a 10-base frameshift deletion at the beginning of exon 7. Therefore, these previous data and our present work make very likely that the other observed variants that involve exon 7 splicing consensus sequences such as IVS6-1G>T, IVS6-2A>C, IVS6-2A>T and IVS6-3C>G (BIC database) lead to the same splicing product.

The *BRCA2* c. 7617+1G>A (HGVS) mutation has been reported four times in the BIC database (IVS15+1G>A), and a similar variant (IVS15+1G>T) has been reported once. The *BRCA2* IVS15+1G>A mutation affects the first position of intron 16, and can be considered pathogenic. We have demonstrated that it causes skipping of exon 15, with the inclusion of 7 new amino acids in the *BRCA2*

protein and the appearance of a premature stop codon. Other variants reported in BIC that affect exon 15 splicing consensus sequences, such as IVS15+2T>G and IVS15+4T>C, could probably lead to the same splicing product but as far as we know no mRNA analysis has been reported (see article note).

In conclusion, our study has evaluated the *BRCA1* c. 302-1G>A variant and the *BRCA2* c. 7617+1G> variant located within intron-exon boundaries. We have demonstrated that both mutations cause frameshift in the translational reading frame, contributing to the pathogenesis of breast and/or ovarian cancer.

References

1. Miki Y, Swensen J, Shattuck-Eidens D et al (1994) A strong candidate for the breast and ovarian cancer susceptibility gene *BRCA1*. *Science* 266:66–71. doi:10.1126/science.7545954
2. Wooster R, Bignell G, Lancaster J et al (1995) Identification of the breast cancer susceptibility gene *BRCA2*. *Nature* 378:789–792. doi:10.1038/378789a0
3. BIC <http://research.nhgri.nih.gov/bic>
4. Krawczak M, Reiss J, Cooper DN (1992) The mutational spectrum of single base-pair substitutions in mRNA splice junctions of human genes: causes and consequences. *Hum Genet* 90:41–54. doi:10.1007/BF00210743
5. Xu CF, Chambers JA, Nicolai H et al (1997) Mutations and alternative splicing of the *BRCA1* gene in UK breast/ovarian cancer families. *Genes Chromosomes Cancer* 18:102–110. doi : 10.1002/(SICI)1098-2264(199702)18:2<102::AID-GCC4>3.0.CO;2-6
6. Scholl T, Pyne MT, Russo D et al (1999) *BRCA1* IVS161 6T4C is a deleterious mutation that creates an aberrant transcript by activating a cryptic splice donor site. *Am J Med Genet* 85:113–116. doi :10.1002/(SICI)1096-8628(19990716)85:2<113::AID-AJMG3>3.0.CO;2-V
7. Pyne MT, Brothman AR, Ward B et al (2000) The *BRCA2* genetic variant IVS7+2T>G is a mutation. *J Hum Genet* 45:351–357. doi:10.1007/s100380070007
8. Laskie Ostrow K, Di Cioccio RA, McGuire V et al (2001) A *BRCA1* variant, IVS23+1 G>A, causes abnormal RNA splicing by deleting exon 23. *Cancer Genet Cytogenet* 127:188–190. doi: 10.1016/S0165-4608(01)00433-2
9. Vega A, Campos B, Bressac de Paillerets B et al (2001) The R71G *BRCA1* is a founder Spanish mutation and leads to aberrant splicing of the transcript. *Hum Mutat* 17:520–521. doi: 10.1002/humu.1136
10. Campos B, Diez O, Domenech M (2003) RNA analysis of eight *BRCA1* and *BRCA2* unclassified variants identified in breast/ovarian cancer families from Spain. *Hum Mutat* 22:337. doi: 10.1002/humu.9176
11. Brose MS, Volpe P, Paul K et al (2004) Characterization of two novel *BRCA1* germ-line mutations involving splice donor sites. *Genet Test* 8:133–138
12. Tesoriero AA, Wong EM, Jenkins MA et al (2005) Molecular characterization and cancer risk associated with *BRCA1* and *BRCA2* splice site variants identified in multiple-case breast cancer families. *Hum Mutat* 26:495. doi:10.1002/humu.9379
13. Bonnati F, Pepe C, Tancredi M et al (2006) RNA-based analysis of *BRCA1* and *BRCA2* gene alterations. *Cancer Genet Cytogenet* 170:93–101. doi:10.1016/j.cancergencyto.2006.05.005

14. Bonnet C, Krieger S, Vezain M et al (2008) Screening BRCA1 and BRCA2 unclassified variants for splicing mutations using reverse transcription PCR on patient RNA and an ex vivo assay based on a splicing reporter minigene. *J Med Genet* 45:438–446. doi:[10.1136/jmg.2007.056895](https://doi.org/10.1136/jmg.2007.056895)
15. Southey MC, Tesoriero A, Young MA et al (2003) A specific GFP expression assay, penetrance estimate, and histological assessment for a putative splice site mutation in *BRCA1*. *Hum Mutat* 22:86–91. doi:[10.1002/humu.10224](https://doi.org/10.1002/humu.10224)
16. Chen X, Truong TTN, Weaver JE et al (2006) Intronic alterations in *BRCA1* and *BRCA2*: effect on mRNA splicing fidelity and expression. *Hum Mutat* 27:427–435. doi:[10.1002/humu.20319](https://doi.org/10.1002/humu.20319)